TOKYO, Jan 11, 2023 – (JCN Newswire via SEAPRWire […]
Tag: alzheimer’s
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
TOKYO, Jan 9, 2023 – (JCN Newswire via SEAPRWire. […]
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
TOKYO, Nov 30, 2022 – (JCN Newswire via SEAPRWire […]
Eisai’s Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer’s Disease, in Thailand
TOKYO, Nov 4, 2022 – (JCN Newswire via SEAPRWire. […]
Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022
TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire […]
U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab
TOKYO, Jul 6, 2022 – (JCN Newswire via SEAPRWire. […]